Primary and secondary prevention of cervical cancer - Opportunities and challenges

Journal of the National Cancer Institute

Volumn 101, Issue 7, 2009, Pages 439-440

  Markowitz, Lauri E ^a   Unger, Elizabeth R ^b   Saraiya, Mona ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; CANCER VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; EDITORIAL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPANICOLAOU TEST; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOLOGY; MASS SCREENING; METHODOLOGY; NOTE; ORGANIZATION AND MANAGEMENT; UNITED STATES; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ALPHAPAPILLOMAVIRUS; CANCER VACCINES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; NEW MEXICO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PRIMARY PREVENTION; RESEARCH DESIGN; SECONDARY PREVENTION; TUMOR VIRUS INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 63649131050     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp044     Document Type: Editorial

References (17)

1. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
2. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent Ll virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-2170.
3. Shefer A, Markowitz L, Deeks S, et al. Early experience with human papillomavirus vaccine introduction in the United States, Canada, and Australia. Vaccine. 2008;26(S10):K68-K75.
4. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programs among high income countries, June 2006-January 2008. Vaccine. 2008;26(19):6529-6541.
5. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(53):S171-S177.
6. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cervical cancer screening in the United States. ? Natl Cancer Inst. 2009;101(7):1-13.
7. Munoz N, Bosch FX, de Sanjosae S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
8. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNAtestingandHPV-16, 18 vaccination. J Natl Cancer Inst. 2008;100(5): 308-320.
9. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008;26s:A16-A23.
10. Waxman AG. Cervical cancer screening in the early post vaccine era. Obstet Gynecol Clin North Am. 2008;35(4):537-548.
11. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362.
12. Saint M, Gildengorin G, Sawaya GF. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. Am J Obstet Gynecol. 2005;192(2)414-421.
13. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40):1100-1103.
14. Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007;197(1)47.e1-e8.
15. Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113 (10 suppl):2841-2854.
16. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41.
17. Centers for Disease Control and Prevention. Immunization information systems progress-United States, 2006. MMWR Morb Mortal WkIy Rep. 2008;57(11):289-291.